212 related articles for article (PubMed ID: 27799281)
1. Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote.
Otani R; Uzuka T; Ueki K
Jpn J Clin Oncol; 2017 Jan; 47(1):2-6. PubMed ID: 27799281
[TBL] [Abstract][Full Text] [Related]
2. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
4. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
6. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
8. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
9. Practice of IDH1, ATRX, and P53 Immunohistochemistry in Integrated Diagnosis of Adult Diffuse Gliomas: Single Center Study.
Shabanzadeh Nejabad Z; Mabroukzadeh Kavari H; Saffar H; Tavangar SM; Sefidbakht S; Khoshnevisan A; Zare-Mirzaie A; Vasei M; Jafari E; Yaghmaii M; Saffar H
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):390-398. PubMed ID: 37278280
[TBL] [Abstract][Full Text] [Related]
10. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
[TBL] [Abstract][Full Text] [Related]
11. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of molecular biomarkers in gliomas.
Siegal T
J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211
[TBL] [Abstract][Full Text] [Related]
13. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
14. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
Haberler C; Wöhrer A
Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763
[TBL] [Abstract][Full Text] [Related]
15. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
16. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
17. Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.
Zepeda-Mendoza CJ; Vaubel RA; Zarei S; Ida CM; Matthews M; Acree S; Raghunathan A; Giannini C; Jenkins RB
Acta Neuropathol; 2020 Jun; 139(6):1105-1107. PubMed ID: 32170402
[No Abstract] [Full Text] [Related]
18. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.
Brandner S; von Deimling A
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653
[TBL] [Abstract][Full Text] [Related]
19. Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood.
Huse JT
Surg Pathol Clin; 2016 Sep; 9(3):379-90. PubMed ID: 27523967
[TBL] [Abstract][Full Text] [Related]
20. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
Rajeswarie RT; Rao S; Nandeesh BN; Yasha TC; Santosh V
J Clin Pathol; 2018 Apr; 71(4):323-329. PubMed ID: 28801347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
